MEGACE
LOE ApproachingNDAORALSUSPENSION
Approved
Sep 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
MEGACE by Bristol Myers Squibb is cachexia. Approved for anorexia, cachexia, an unexplained significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (aids). First approved in 1993.
Drug data last refreshed 3h ago
Worked on MEGACE at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.